Amb-pinaca is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ -THC in rat discrimination studies, while being 1.5x more potent. The potency and bioavailability of AB-PINACA are similar to those of other synthetic cannabinoids such as JWH-015 and JWH-073. AB-PINACA is a more selective CB1 receptor agonist than other synthetic cannabinoids, with a greater inhibition of the CB1 receptor than of the CB2 receptor. A further advantage of AB-PINACA is that it does not produce the pronounced psychoactivity of other synthetic cannabinoids. AB-PINACA is not a cannabinoid but a synthetic analogue of a psychoactive drug. As a result, it has no potential for abuse liability or harm. As of October 20, 2016, Amb-pinaca is a controlled substance (Schedule 9 in the UK) in Sweden, a Schedule 9 controlled substance in the USA (BUNS Schedule 1 in Canada) and Australia, as well as a schedule 9 controlled substance in New Zealand.
- Product Name:AMB-PINACA
- IUPAC Name: N-[(1-pentyl-1H-indazol-3-yl)carbonyl]-L-valine, methyl ester
- Other Names:AMB-PINACA
- Cas Number:1890250-13-1
- Molecular Formula: C19H27N3O3
- Appearance: Crystalline solid and powder
- Application: Research purposes
- Availability: In Stock
- Packaging: Aluminum foil bag package done by an expert
- Purity: 99.8%
- Origin: China
- Minimum order: 10 Grams
- Production Capacity: 100KG/WEEK
- Transportation: Delivery done by EMS, DHL, FEDEX, UPS and TNT
Currently, amb-pinaca is marketed under the brand name Euprostenol by Saito Pharmaceutical Co., Ltd in Japan and is available by prescription. The following is a crude amb-pinaca molecule: amb-pinaca is the 7-Hydroxy-3-Hydroxypiperidine analogue of CBG, the 4-Hydroxy-3-Hydroxypiperidine analogue of THCB and the 6-Hydroxy-2,5-Dimethoxycathinone analogue of DKC. AB-PINACA has a pharmacological profile similar to piperazines. It exhibits an anxiolytic-like and mild sedative-hypnotic-like profile. In rats, AB-PINACA has elicited significantly lower heart rate (HR) and reduced pupil size, sedation, respiratory depression, analgesia, and sedation than placebo. It has also shown positive effects on memory, a rating scale for emotion, and cognition in a preliminary study in humans. However, long-term use of AB-PINACA has not been tested, and the clinical toxicity of this drug has not yet been studied.
Preliminary reports indicate amb-pinaca produces similar effects as endocannabinoids, and likely operates by activation of cannabinoid CB receptors. However, the clinical effectiveness of this compound in humans has not been established. Amb-pinaca has been reported to possess hallucinogenic, hallucinogenic and dissociative effects in humans. Amb-pinacainduces a range of subjective effects, including stimulation, elevated mood, anhedonia, and eye redness, during use. It is a good match for the “IP” in psilocin. In rats, AB-PINACA is reported to produce comparable drug effects to the psychedelic phenethylamine N,N-dimethyltryptamine (DMT) and the hallucinogenic tryptamine psilocybin, but less intense than those of the hallucinogenic 5-MeO-DMT. Moreover, because Amb-pinaca produces no loss of inhibition or serotonin-dopamine release, it has been suggested that it may be less problematic than other tryptamines.
These characteristics are comparable to those of ketamine and nitrous oxide but unlike the psychedelic phenethylamines. Neuropharmacological studies in humans, however, have not been performed in the treatment of addiction. While the mechanisms of action of amb-pinaca are not well characterized, one pharmacological action of the tryptamines is that of inhibition of the reuptake of serotonin. It has been speculated that, in addition to its role as an antagonist of serotonin receptors, amb-pinata might also act as a serotonin-norepinephrine reuptake inhibitor